TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel
TC BioPharm (NASDAQ: TCBP) is a clinical-stage cell therapy company focused on the development of treatments for infectious diseases, including advanced allogeneic chimeric antigen receptor (CAR) T-cell therapy products for […]
The post TC BioPharm develops safer, less expensive products to target more cancers: CEO Bryan Kobel first appeared on AlphaStreet.